SEC Form 6-K filed by Alpha Tau Medical Ltd.

$DRTS
Medical/Dental Instruments
Health Care
Get the next $DRTS alert in real time by email
6-K 1 ea022499601-6k_alphatau.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December 2024

 

Commission File Number: 001-41316

 

 

 

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒            Form 40-F  ☐

 

 

 

 

CONTENTS

 

On December 17, 2024, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

 

The information in this Report on Form 6-K, including in Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

 

1

 

 

EXHIBIT INDEX

Exhibit

No.

  Description
   
99.1   Press release dated December 17, 2024.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Alpha Tau Medical Ltd.
     
Date: December 17, 2024 By:  /s/ Uzi Sofer
    Uzi Sofer
    Chief Executive Officer

  

3

 

 

Get the next $DRTS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DRTS

DatePrice TargetRatingAnalyst
12/15/2023$8.00Buy
Citigroup
4/24/2023$9.00Buy
H.C. Wainwright
4/14/2022$20.00Overweight
Cantor Fitzgerald
4/8/2022$19.00Overweight
Piper Sandler
4/4/2022$21.00Buy
Citigroup
More analyst ratings

$DRTS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

    - Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement t

    $DRTS
    Medical/Dental Instruments
    Health Care
  • Alpha Tau to Participate in March Investor Conferences

    JERUSALEM, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the following investor conferences in March 2025. Event:Investor Summit EventFormat:PresentationDate:March 11, 2025Time:12:00PM – 12:30PM ETLocation:Virtual Event:Oppenheimer 35th Annual Healthcare MedTech & Services ConferenceFormat:PresentationDate:March 17, 2025Time:3:20PM – 3:50PM ETLocation:Virtual Event:Sidoti Small Cap ConferenceFormat:PresentationDate:March 19, 2025Time:11:30AM – 12:00PM ETLocation:Virtual Mr. Levy wi

    $DRTS
    Medical/Dental Instruments
    Health Care
  • Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

    JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the achievement of Medical Device Single Audit Program (MDSAP) certification for the company's manufacturing facility in Jerusalem, as part of the Company's commitment to quality, safety, and regulatory compliance while accelerating the global expansion of alpha-radiation cancer therapy through the manufacturing of the Alpha DaRT. MDSAP was established by a coalition of international medical device regulatory authorities from Australia, Brazil, Canada, Japan and the U.S., to

    $DRTS
    Medical/Dental Instruments
    Health Care

$DRTS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$DRTS
SEC Filings

See more

$DRTS
Leadership Updates

Live Leadership Updates

See more
  • Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

    - Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement t

    $DRTS
    Medical/Dental Instruments
    Health Care
  • Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

    JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company's Board of Directors ("Board"). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity. "I am delighted to welcome Maya to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "Maya brings a wealth of experience and a keen under

    $DRTS
    Medical/Dental Instruments
    Health Care
  • Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

    JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company's Board of Directors in order to assume the full-time position of Alpha Tau's Chief Commercial Officer. Mr. Melnyk served most recently as CEO of Fortovia Therapeutics, an oncology supportive care pharmaceutical and medical device company headquartered in Raleigh, North Carolina. Before that, he served as Chief Commercial Officer of Novocure, and led the construction of the global commercial platform and infrastructure

    $DRTS
    Medical/Dental Instruments
    Health Care